Abou-Alfa, Ghassan K.; Galle, Peter R.; Chao, Yee et al.
PHOCUS: A Phase 3, Randomized, Open-Label Study of Sequential Treatment with Pexa-Vec (JX-594) and Sorafenib in Patients with Advanced Hepatocellular CarcinomaLIVER CANCER. 2023
Abou-Alfa, Ghassan K.; Lau, George; Kudo, Masatoshi et al.
Plain language summary of the HIMALAYA study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer)FUTURE ONCOLOGY. 2023
Stortz, Marco; Shmanko, Kateryna; Kraus, Daniel et al.
Plasma exchange for treatment of a therapy-related thrombotic microangiopathy in a patient with advanced hepatocellular carcinoma-A case reportCLINICAL CASE REPORTS. Bd. 11. H. 11. 2023
Boeckmans, Joost; Gatzios, Alexandra; Schattenberg, Joern M. et al.
PNPLA3 I148M and response to treatment for hepatic steatosis: A systematic reviewLIVER INTERNATIONAL. Bd. 43. H. 5. 2023 S. 975-988
Witzel, Hagen Roland; Schwittai, Inga Maria Gertrud; Hartmann, Nils et al.
PNPLA3(I148M) Inhibits Lipolysis by Perilipin-5-Dependent Competition with ATGLCELLS. Bd. 12. H. 1. 2023
Castven, Jovana; Becker, Diana; Heinrich, Sophia et al.
Poor sorafenib response in hepatocellular carcinoma patients is mediated by hypoxia-related 14-3-3 scaffolding proteins andJOURNAL OF HEPATOLOGY. Bd. 78. 2023 S. S557-S557
Schleicher, Eva Maria; Kaps, Leonard; Schattenberg, Joern et al.
Poorer results in the clinical frailty scale are associated with covert and overt hepatic encephalopathy in patients with cirrhosisJOURNAL OF HEPATOLOGY. Bd. 78. 2023 S. S271-S272
Mueller, Lukas; Gairing, Simon J.; Foerster, Friedrich et al.
Portal hypertension in patients with hepatocellular carcinoma and immunotherapy: prognostic relevance of CT-morphologic estimatesCANCER IMAGING. Bd. 23. H. 1. 2023
Staudacher, Jonas J.; Backes, Moritz; Bettinger, Dominik et al.
Position Paper "University Career Paths"ZEITSCHRIFT FUR GASTROENTEROLOGIE. Bd. 61. H. 08. 2023 S. 997-999
Castven, Darko; Keggenhoff, Friederike; Stojkovic, Stojan et al.
Positive effects of PARP-1 inhibition in KRAS-mutated intrahepatic cholangiocarcinoma is mediated by CHK1 kinaseJOURNAL OF HEPATOLOGY. Bd. 78. 2023 S. S536-S537